Drug intelligence / Profile preview

Tianfoshen Oral Liquid

Development stage: Unknown
Lead developer: Changshu Leiyunshang Pharmaceutical
Administration: Oral

Overview

Tianfoshen Oral Liquid is a Traditional Chinese Medicine (TCM) developed and manufactured by Anhui Leiyunshang Pharmaceutical. It is approved in China as an adjuvant therapy for malignant tumors, particularly for patients undergoing chemotherapy or radiotherapy for lung cancer and gastrointestinal cancers. The formulation is composed of several botanical extracts, including Ginseng, Poria cocos, and Sophora flavescens, which are intended to tonify "Qi" and nourish "Yin." Clinically, it is used to enhance immune function, increase white blood cell counts, and improve the overall quality of life and treatment tolerance in oncology patients exhibiting deficiency symptoms.

Brand names: Tianfoshen Oral Liquid
Other names: TianfoshenTianfoshen Koufuye天佛参口服液

Beyond the preview

Go deeper on Tianfoshen Oral Liquid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tianfoshen Oral Liquid.

Explore the full profile